France's life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé…

After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed,…

Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers…

Ipsen's George Carystinos explains what brought him back to Greece for a first country manager position after a succession of global roles, how the…

The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving…

As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma…

General manager of MEA, Khaled Elrefae, explains how Ipsen has strengthened its footprint in the region over the past two years - starting in the UAE…

Recent announcements from Ipsen and AbbVie of multimillion Euro investments into Irish manufacturing plants underline the Celtic nation’s continuing…

Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few…

Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20…

French mid-cap Ipsen has signed an agreement to acquire US-based oncology specialist Epizyme, with its lymphoma drug, Tazverik, for USD 247 million to…

Ipsen's Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and…